While pharmacological or genetic inhibition of C5aR1 in stroke and spinal cord injury has shown neuroprotective effects in several studies, here we showed that inhibition of C5aR1 did not ameliorate tissue loss or neurological deficits in TBI, despite decreasing immune cell counts in the injured brain [46–48]. Here, C5AR1 is linked to stroke disorder.